Elena Dneprovskaia

Phosphoinositide 3-kinase γ/δ inhibition limits infarct size after myocardial ischemia/reperfusion injury

John Doukas, Wolfgang Wrasidlo, Glenn Noronha et al. · Proceedings of the National Academy of Sciences · 2006 · 130 citations · Full text

Medicine, Cardiology, Pharmacology +14

Aerosolized Phosphoinositide 3-Kinase γ/δ Inhibitor TG100-115 [3-[2,4-Diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a Therapeutic Candidate for Asthma and Chronic Obstructive Pulmonary Disease

John Doukas, Lisa Eide, Karin J. Stebbins et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 102 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRβ/B-RAF

Eric A. Murphy, David J. Shields, Konstantin Stoletov et al. · Proceedings of the National Academy of Sciences · 2010 · 59 citations · Full text

Pharmacy, Oncology, Pharmacology +15

Discovery of 3,3‘-(2,4-Diaminopteridine-6,7-diyl)diphenol as an Isozyme-Selective Inhibitor of PI3K for the Treatment of Ischemia Reperfusion Injury Associated with Myocardial Infarction

Moorthy S. S. Palanki, Elena Dneprovskaia, John Doukas et al. · Journal of Medicinal Chemistry · 2007 · 55 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine—a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays

Glenn Noronha, Kathy Barrett, Antonio Boccia et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 47 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15